Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

NCT: NCT05683691 · ACTIVE_NOT_RECRUITING

NCT IDNCT05683691
StatusACTIVE_NOT_RECRUITING
Start Date2023-05-16
Completion2029-04

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.

Frequently Asked Questions

What is Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer?

Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer is a clinical trial registered under NCT05683691. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05683691?

The current status of NCT05683691 (Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer) is: ACTIVE_NOT_RECRUITING.

When did Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer start?

Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer started on 2023-05-16.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑